Inside U.S. Trade reports that USTR intends to table a full intellectual property chapter for the TPP by mid June, and that the pharmaceutical industry has been lobbying to reverse the policy deal struck by the Bush Administration and Congressional Democrats on May 10, 2007.  The leaked intellectual property text that has circulated leaves out the controversial provisions covered by the agreement: data exclusivity, patent extensions, and linkage between patent offices and health regulators.  The pharmaceutical industry wants USTR to use the Korea-US FTA language as a template for these provisions in the TPP, while health advocates want the May 10, 2007 Agreement to serve as a starting point for increasing countries’ flexibility in accessing generic medicines.